Risk Based Regulations for Natural Health Products


Health Canada

Project description

Through Canada's product regulatory system, government plays a lead and essential role in protecting the health and safety of Canadians. Citizens have high standards and expectations, both for the products they receive, and the government that regulates those products. However, unprecedented scientific advances and the growing economic importance of international trade are increasingly challenging the system. Canada’s regulatory system is founded upon exclusive product category definitions (food, drug, medical device, and recently natural health products) and their appropriate risk-management frameworks. However, new advances in science and technology are fuelling a significant increase in products that combine or move across existing regulatory product definitions and thus current regulatory approaches are becoming increasingly ambiguous or inadequate.

Four combination product were selected for this project (device-drug, device-NHP, NHP-drug, and NHP-food) because of their safety and efficacy issues, increasing prevalence in the market, exclusion from existing regulatory frameworks, and their innovative science, technological, and clinical applications. These qualities make them unique regulatory challenges, and in each case, the development of new definitions and policy frameworks will require the involvement and cooperation of a wide range of stakeholders. Four jurisdictions were chosen for assessment, the United States, Australia, EU, and Japan. These jurisdictions generally follow one of two approaches for risk assessment of new health products: risk-based classification rules or a product or panel based approach.

The research objectives are to:
This will result in a set of prioritized risk-based regulatory recommendations (best practices, lessons learned) for combination products for Health Canada's consideration.

<< Back to featured projects